Discover Our Group:

Berlin-Chemie has been developing, manufacturing and distributing pharmaceutical products for over 130 years and has been a wholly owned subsidiary of the Menarini Group, the leading Italian pharmaceutical company, since 1992. 

Responsibility is a top priority at Berlin-Chemie. We not only make an important contribution to healthcare, but also put our values into practice through various social initiatives.

Discover More about Global Responsibility

From school kits to free meals and medicines, to caring for the environment around the world. In Menarini, being responsible means translating our values into concrete actions that are good for others and good for the planet

Berlin-Chemie – a strong partner. Our many years of experience and the success of joint projects make us the partner of choice. 

Discover More about Global Partnering

Menarini has in-depth know-how in many important therapeutic areas, thanks to many years of excellent market introduction, marketing and sales capabilities as well as expertise in regulatory aspects and market access. Collaboration is the key to great success, and at Menarini, partnership is part of the DNA.

Our holistic and professional health management offers doctors individual counselling, training or workshops, events and lectures on many topics, depending on their needs.

Our Medical Hub acts as a central point of contact for doctors and healthcare professionals. Here you will find all the information about our medications, additional service and training opportunities.

Welcome to the News & More section. Here you will find general information in the form of press releases, news and the latest graphical material. 

Menarini Blog

Follow Us

We employ professionals with a wide variety of career backgrounds and are employers who care about their staff. Together, we stand for innovation and reliability.

Our Job Portal

Find out about our current vacancies at Berlin-Chemie directly on our career portal.

Menarini Group News

2011 - 06 - 06

The mimosa study: expectations blighted, sense of pride remains high



Chicago, 6th June 2011 - At the American Society of Clinical Oncology Congress (ASCO), the outcome of the MIMOSA Study on the potential benefit of Abagovomab, a molecule developed by Menarini Research, on the ”time to relapse” in women suffering from ovarian cancer, was presented. The study lasted four years and involved approximately 900 patients in 150 specialised centres throughout Europe and U.S.A.

Even if the treatment itself has been well tolerated, the vaccinations carried out using Abagovomab did not confirm the expected levels of benefit foreseen during the initial studies.

“The members of the Menarini Research department, a predominantly female team, have never considered this project just another part of their daily work. They have always considered it a true mission to stand by all those women who, every day of their lives, have to fight against this ‘silent killer’. Results such as these, despite the excellent scientific promise of the project as a whole, are one of those ‘surprises’ that often, and unfortunately, do occur during the development of highly innovative drugs and one that we, as a company, are called to face. The results of the Mimosa Study are, however, to be considered a precious contribution to the world’s scientific community as, with their thoroughness and calibre, they lead the way to new and different inroads into oncological research on an International level. Our commitment and undertaking to stand by all those women in their fight against ovarian cancer, just like all our other research work, are not, therefore, to be considered worthless”, commented Angela Capriati, Director of Clinical Research at Menarini.

Particular thanks were extended to all those oncologists and patients who participated in the study.

“The MIMOSA project has been brought forward by Menarini, heads high, with the esteem of the world’s oncological community and has left us with an extraordinary degree of experience and scientific skill which will contribute towards advancing all those ambitious research projects currently on-going”, reassured Carlo Alberto Maggi, Director of Research and Development within the Menarini Group, “the high level of commitment in bringing forward innovative Research projects for the treatment of hereunto unresolved diseases remains unchanged.”